TrialBMC cancer2018

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

Gabriel Rinnerthaler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.